Tags

Type your tag names separated by a space and hit enter

Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
Ren Fail 2007; 29(6):713-9RF

Abstract

BACKGROUND

Apolipoprotein-E (ApoE) gene polymorphism has an important role in lipoprotein metabolism and could participate in the development of cardiovascular diseases (CVD). Plasminogen activator inhibitor-1 (PAI-1) is also regarded as a risk factor for CVD. The aim of the present study is to further investigate the possible link(s) between ApoE gene polymorphism and plasma PAI-1 antigen and serum lipid profile in peritoneal dialysis (PD) and hemodialysis (HD) patients.

MATERIAL AND METHODS

We studied 72 PD patients (38 female, mean age 49.9 +/- 16.1 years), 72 HD patients (22 female, mean age 57.4 +/- 14.6 years), and 42 healthy subjects (21 female, mean age 50.1 +/- 18.6 years). Serum lipid parameters, plasma PAI-1 levels, and ApoE genotypes were determined in all subjects.

RESULTS

The distribution of ApoE genotypes and alleles frequencies was similar in dialysis patients and healthy controls. In PD patients, total cholesterol (TC), low-density lipoprotein (LDL)-C, and ApoB levels were significantly higher than that of HD patients. HD patients with E3/4 genotype had elevated TC, LDL-C and ApoB levels compared with E3/3 genotype. TC and triglyceride levels were also higher in E3/4 genotype than that of E2/3 genotype. PD and HD patients showed a significantly increased PAI-1 levels compared with controls, whereas PAI-1 levels were highest in HD patients. There was no significant relation between ApoE genotypes and PAI-1 levels.

CONCLUSIONS

The present study suggests that ApoE polymorphism significantly affects serum lipid profile in HD patients and epsilon4 allele carriers are more susceptible to have atherogenic lipid profile.

Authors+Show Affiliations

Division of Nephrology, Department of Medicine, Marmara Medical School, Istanbul, Turkey. ihakkiarikan@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17763167

Citation

Arikan, Hakki, et al. "Associations Between Apolipoprotein E Gene Polymorphism and Plasminogen Activator Inhibitor-1 and Atherogenic Lipid Profile in Dialysis Patients." Renal Failure, vol. 29, no. 6, 2007, pp. 713-9.
Arikan H, Koc M, Sari H, et al. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Ren Fail. 2007;29(6):713-9.
Arikan, H., Koc, M., Sari, H., Tuglular, S., Ozener, C., & Akoglu, E. (2007). Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Renal Failure, 29(6), pp. 713-9.
Arikan H, et al. Associations Between Apolipoprotein E Gene Polymorphism and Plasminogen Activator Inhibitor-1 and Atherogenic Lipid Profile in Dialysis Patients. Ren Fail. 2007;29(6):713-9. PubMed PMID: 17763167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. AU - Arikan,Hakki, AU - Koc,Mehmet, AU - Sari,Hakan, AU - Tuglular,Serhan, AU - Ozener,Cetin, AU - Akoglu,Emel, PY - 2007/9/1/pubmed PY - 2007/11/6/medline PY - 2007/9/1/entrez SP - 713 EP - 9 JF - Renal failure JO - Ren Fail VL - 29 IS - 6 N2 - BACKGROUND: Apolipoprotein-E (ApoE) gene polymorphism has an important role in lipoprotein metabolism and could participate in the development of cardiovascular diseases (CVD). Plasminogen activator inhibitor-1 (PAI-1) is also regarded as a risk factor for CVD. The aim of the present study is to further investigate the possible link(s) between ApoE gene polymorphism and plasma PAI-1 antigen and serum lipid profile in peritoneal dialysis (PD) and hemodialysis (HD) patients. MATERIAL AND METHODS: We studied 72 PD patients (38 female, mean age 49.9 +/- 16.1 years), 72 HD patients (22 female, mean age 57.4 +/- 14.6 years), and 42 healthy subjects (21 female, mean age 50.1 +/- 18.6 years). Serum lipid parameters, plasma PAI-1 levels, and ApoE genotypes were determined in all subjects. RESULTS: The distribution of ApoE genotypes and alleles frequencies was similar in dialysis patients and healthy controls. In PD patients, total cholesterol (TC), low-density lipoprotein (LDL)-C, and ApoB levels were significantly higher than that of HD patients. HD patients with E3/4 genotype had elevated TC, LDL-C and ApoB levels compared with E3/3 genotype. TC and triglyceride levels were also higher in E3/4 genotype than that of E2/3 genotype. PD and HD patients showed a significantly increased PAI-1 levels compared with controls, whereas PAI-1 levels were highest in HD patients. There was no significant relation between ApoE genotypes and PAI-1 levels. CONCLUSIONS: The present study suggests that ApoE polymorphism significantly affects serum lipid profile in HD patients and epsilon4 allele carriers are more susceptible to have atherogenic lipid profile. SN - 0886-022X UR - https://www.unboundmedicine.com/medline/citation/17763167/Associations_between_apolipoprotein_E_gene_polymorphism_and_plasminogen_activator_inhibitor_1_and_atherogenic_lipid_profile_in_dialysis_patients_ L2 - http://www.tandfonline.com/doi/full/10.1080/08860220701460129 DB - PRIME DP - Unbound Medicine ER -